Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low level laser or LED therapy combined with infiltrations may help hair growth.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study found that low-level laser therapy effectively reduced relapse rates, while functional appliances did not; combining them offered no additional benefits.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This review categorizes 59 modifications of the Dermatology Life Quality Index across multiple studies, highlighting the need for further validation of these customized health-related quality of life tools in dermatology.

This review highlights LTBP1 as a critical integrator in disease processes, showing its dual role in cancer progression and suppression, its pathological influence in fibrosis, and its contribution to various disorders, suggesting its potential as a biomarker and therapeutic target.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This study found that lead treatment enhances the imaging of organized hair lipid structures, revealing their orientation and possible composition as lead and calcium soaps, with potential applications in various fields.

This study found that low-intensity light therapy improved quality of life related to emotional, psychosocial, and symptom domains in individuals with androgenic alopecia, with a greater impact observed in women.

This article reviews the role of LMNA gene mutations, particularly in Hutchinson–Gilford progeria syndrome, but does not report new experimental findings.

This study developed a reliable RP-HPLC method for the simultaneous estimation of Spironolactone and Hydrochlorothiazide, which was validated as accurate, precise, and robust for pharmaceutical applications.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This case report highlights a 21-year-old woman with seizures, mental retardation, spastic diplegia, and ichthyosis consistent with Sjogren-Larsson syndrome, and emphasizes the importance of differential diagnosis when additional symptoms are present.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This study found that the transcription factor GLABRA 2 inhibits ethylene production, regulating root hair growth in Arabidopsis under nutrient deficiency conditions.

In this case study, researchers identified a Leydig cell tumor in a 56-year-old postmenopausal woman with virilization symptoms by using ovarian vein sampling, as imaging was nonrevealing, and confirmed the tumor's location using testosterone ratios, which supported previous findings.

I cannot provide a conclusion without the content of the document.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

This study observed that some patients with homozygous c.736T>A mutation in LIPH may have mild hypotrichosis with long hairs in adulthood.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

The conclusion is that a new method to measure hair shine was confirmed to match people's visual assessments.